** Shares of drugmaker Invivyd IVVD.O fall 37.2% to $1.11 premarket
** Co says the U.S. FDA has declined to expand the emergency use authorization of its COVID-19 prevention drug
** The expansion was to include those whose immunity is impaired by certain conditions such as cancer and organ transplant, and for whom alternative options are not accessible or appropriate
** The drug Pemgarda is already authorized for emergency use in those with compromised immunity due to a medical condition or receiving medicines that suppress the immune system, and unlikely to have an adequate response to vaccination
** IVVD fell 88.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。